USPTO issues Notice of Allowance for Quick-Med Technologies' NIMBUS technology

Quick-Med Technologies, Inc. (OTCBB:QMDT), a leader in developing innovative antimicrobial technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that significantly adds to the current patent coverage for the Company's NIMBUS technology.

The Notice of Allowance covers patent claims that address the bonding of the NIMBUS polymeric antimicrobial to a variety of base materials including woven and nonwoven fabrics. The broad range of materials includes those that are composed of natural fibers, such as cotton and wool, as well as synthetics such as polyurethane, polyester, nylon and polypropylene. The applications included in the allowed claims are for a full spectrum of products such as medical devices including wound and burn dressings and blood transfer and storage products, surgical drapes and apparel, industrial and military protective wear and consumer apparel plus hygienic products such as wipes, diapers and feminine care.

"This Notice of Allowance further validates the innovative nature of Quick-Med's proprietary NIMBUS technology platform and underscores our company's leadership in developing the first non-leaching antimicrobial available in a wound dressing," said J. Ladd Greeno, Quick-Med's CEO. "We believe that being the only non-leaching antimicrobial dressing represents an important distinction.  Other antimicrobial dressings rely on the release of chemicals into the wound bed that can impede the wound healing process."

NIMBUS technology employs a safe, eco-friendly active agent that remains in full concentration on any of several substrates. It controls a broad range of both Gram-positive and Gram-negative bacteria. The NIMBUS antimicrobial is not depleted in use, maintains effectiveness even in the presence of large amounts of blood or body fluids, and by design, poses no risk of bacteria developing resistance.

NIMBUS non-leaching antimicrobial technology was cleared by FDA in 2009 and is available in BIOGUARD™ barrier dressings from Derma Sciences and Medline, under a private label agreement with Derma Sciences. Quick-Med is developing NIMBUS applications in several other advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids.

A Notice of Allowance communicates the Patent Office's determination that the applicant is entitled to a patent under the law. The Company expects the new patent to be issued later this year.